Treatment outcomes of HIV patients with hepatitis B and C virus co-infections in Southwest China: an observational cohort study

Table 2 Effect of HBV and HCV co-infections on death among HIV patients who initiated ART between 2010 and 2018 in Guangxi, China

Coinfection	Number of HIV patients	Deaths	Person-years (PY)	Mortality rate per 100 person-years (95% CI)	HR (95% CI)	P value	aHR^a (95% CI)	P value
Total	58,239	6,916	234,421.19	2.95 (2.88–3.02)
HIV only	46,847	5,366	187,680.8	2.86 (2.78–2.93)	Reference		Reference
HIV + HBV	6,707	797	28,092.09	2.84 (2.65–3.03)	0.99 (0.92–1.07)	0.784	1.42 (1.32–1.54)	< 0.001
HIV + HCV	3,828	590	15,148.30	3.89 (3.59–4.20)	1.35 (1.24–1.47)	< 0.001	1.65 (1.47–1.86)	< 0.001
HIV + HBV + HCV	857	163	3,500.00	4.66 (3.96–5.35)	1.60 (1.37–1.87)	< 0.001	2.23 (1.87–2.66)	< 0.001

CI, Confidence interval; HR, Hazard ratio; aHR, Adjusted hazard ratio; HBV, Hepatitis B virus; HCV, Hepatitis C virus; HIV, Human immunodeficiency virus
^aAdjusted for Age, gender, marital status, route of HIV transmission, CD4 count before ART, WHO clinical stage before ART, initial first-line ART regimen, current ART regimen, duration of using TDF-containing regimens, calendar year of ART initiation

ISSN: 2049-9957